Astellas launches behavioral science initiative to promote early bladder cancer diagnosis

Astellas Pharma has initiated a global campaign to address the critical issue of delayed bladder cancer diagnoses. In collaboration with the World Bladder Cancer Patient Coalition (WBCPC) and behavioral scientists, the company aims to understand the barriers preventing individuals from seeking timely medical attention for bladder cancer symptoms.

Bladder cancer often goes undetected until advanced stages, significantly reducing survival rates. By exploring cultural, emotional, and societal factors influencing patient behavior, Astellas seeks to develop strategies that encourage earlier diagnosis and improve outcomes for those affected by this disease.

This initiative underscores Astellas’ commitment to patient-centric approaches and aligns with the broader efforts within the Leiden Bio Science Park to enhance healthcare through innovative research and collaboration.

Read more here